首页> 外文期刊>Expert opinion on therapeutic targets >Protein kinase C isozymes as potential therapeutic targets in immune disorders
【24h】

Protein kinase C isozymes as potential therapeutic targets in immune disorders

机译:蛋白激酶C同工酶可作为免疫疾病的潜在治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Members of the protein kinase C (PKC) family are key signalling mediators in immune responses, and pharmacological inhibition of PKCs may be useful for treating immune-mediated diseases. Objective: To review and discuss the insights gained so far into various PKC isozymes and the therapeutic potential and challenges of developing PKC inhibitors for immune disorder therapy. Methods: A literature review of the role of PKCs in immune cell signalling and recent studies describing immune functions associated with PKC isozyme deficiency in relevant mouse disease models, followed by specific case studies of current and potential therapeutic strategies targeting PKCs. Results/conclusion: There is vast amount of data supporting PKC isozymes as attractive drug targets for certain immune disorders. Although the development of specific PKC isozyme inhibitors has been challenging, some progress has been made. It remains to be seen if broad-scale or isozyme-selective inhibition of PKC will have clinical efficacy.
机译:背景:蛋白激酶C(PKC)家族的成员是免疫应答中的关键信号传导介质,PKCs的药理抑制作用可能对治疗免疫介导的疾病有用。目的:回顾和讨论迄今为止对各种PKC同工酶的见解,以及开发用于免疫疾病治疗的PKC抑制剂的治疗潜力和挑战。方法:文献综述了PKC在免疫细胞信号传导中的作用,最近的研究描述了相关小鼠疾病模型中与PKC同工酶缺乏相关的免疫功能,然后针对当前和潜在的针对PKC的治疗策略进行了案例研究。结果/结论:有大量数据支持PKC同工酶作为某些免疫疾病的诱人药物靶标。尽管开发特定的PKC同工酶抑制剂具有挑战性,但已经取得了一些进展。 PKC的大规模抑制或同功酶选择性抑制是否具有临床疗效还有待观察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号